Want to see ZNTL full AI Analyst Report?
ZNTL Stock Chart & Stats
$1.41
-$0.17(-5.69%)
At close: 4:00 PM EST
$1.41
-$0.17(-5.69%)
Day’s Range― - ―
52-Week Range$1.21 - $6.95
Previous CloseN/A
Volume750.15K
Average Volume (3M)716.92K
Market Cap
$356.64M
Enterprise Value-$8.69
Total Cash (Recent Filing)$211.76M
Total Debt (Recent Filing)$38.65M
Price to Earnings (P/E)―
Beta3.47
Next Earnings
Aug 12, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding71,186,350
10 Day Avg. Volume819,524
30 Day Avg. Volume716,917
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.67Price Target Upside372.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline ProgressDosing the first patient in a global Phase 3 confirmatory trial materially de-risks the development timeline versus earlier stages. A successful ASPENOVA outcome would support full approval, enable commercialization and create a durable revenue path that underpins long-term business viability.
Dual-track Regulatory StrategyRunning a dual-track strategy (an accelerated-approval enabling trial alongside a confirmatory Phase 3) can shorten time-to-market while preserving a path to full approval. Structurally this reduces regulatory timing risk and gives management multiple paths to commercialize azenosertib if data remain favorable.
Cash Runway And Modest LeverageHaving ~$212 million in cash and runway into late 2027 funds pivotal trials and pre-commercial activities, lowering near-term dilution risk. Modest historical debt (debt-to-equity ~0.19) also preserves financing flexibility, supporting execution of late-stage programs over the next 12–18 months.
Bears Say
No Current RevenueThe company has no sustainable commercial revenue today, meaning long-term value depends on future regulatory success and market uptake. Absent revenue, financing needs and milestone-dependent cash inflows will dominate outcomes and delay positive operating leverage for many quarters.
Persistent Negative Cash FlowLarge, sustained negative operating and free cash flow indicates the business is cash consumptive and reliant on external funding. Even with burn improvement, ongoing negative FCF increases dilution and refinancing risk, constraining long-term flexibility for R&D expansion or commercialization investments.
Concentrated Pipeline / Single-asset RiskBusiness outcomes are highly concentrated around azenosertib and a small number of targeted oncology programs. This creates binary clinical and commercial risk: late-stage trial results will disproportionately determine company success, making future cash flows and profitability contingent on single-asset performance.
Zentalis Pharmaceuticals News
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $1.21 and its highest was $6.95 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $356.64M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 19 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.023.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.49.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 71,186,350 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Currently, no hedge funds are holding shares in ZNTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentalis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.67 (372.81% Upside)
$6.67 (372.81% Upside)
Hedge Fund Trend
Decreased
By 263.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-34.10%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
ZNTL Stock 12 Month Forecast
Average Price Target
$6.67
▲(372.81% Upside)
Technical Analysis
MacroGenics
―
VistaGen Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
Ownership Overview
30.49% Insiders
6.75% Mutual Funds
0.06% Other Institutional Investors
53.81% Public Companies and
Individual Investors